Hasil Pencarian - Hiroshi Kagamu

Perbaiki Hasil
  1. 1
    Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients

    Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients oleh Hiroshi Kagamu, Kyoichi Kaira

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers

    Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers oleh Kyoichi Kaira, Ichiei Kuji, Hiroshi Kagamu

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status

    Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status oleh Kyoichi Kaira, Hisao Imai, Atsuto Mouri, Ou Yamaguchi, Hiroshi Kagamu

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)

    A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0... oleh Kyoichi Kaira, Atsuto Mouri, Shingo Kato, Kenichi Yoshimura, Hiroshi Kagamu, Kunihiko Kobayashi

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer

    Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously tre... oleh Atsuto Mouri, Kyoichi Kaira, Ayako Shiono, Ou Yamaguchi, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu

    Diterbitkan 2019-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Simultaneous development of Graves’ disease and type 1 diabetes during anti‐programmed cell death‐1 therapy: A case report

    Simultaneous development of Graves’ disease and type 1 diabetes during anti‐programmed cell death‐1 therapy: A case report oleh Susumu Kurihara, Yoichi Oikawa, Ritsuko Nakajima, Atsushi Satomura, Ryuhei Tanaka, Hiroshi Kagamu, Akira Shimada

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

    Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy oleh Miren Zuazo, Hugo Arasanz, Ana Bocanegra, Luisa Chocarro, Ruth Vera, David Escors, Hiroshi Kagamu, Grazyna Kochan

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    The Asthma Control Test, Japanese Version (ACT-J) as a Predictor of Global Initiative for Asthma (GINA) Guideline-Defined Asthma Control: Analysis of a Questionnaire-Based Survey

    The Asthma Control Test, Japanese Version (ACT-J) as a Predictor of Global Initiative for Asthma (GINA) Guideline-Defined Asthma Control: Analysis of a Questionnaire-Based Survey oleh Takashi Hasegawa, Toshiyuki Koya, Takuro Sakagami, Hiroshi Kagamu, Masaaki Arakawa, Fumitake Gejyo, Ichiei Narita, Eiichi Suzuki

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Eradication of Established Murine Skin Tumors by Cyclic Chemoimmunotherapy with Cyclophosphamide and Effector T Cells

    Eradication of Established Murine Skin Tumors by Cyclic Chemoimmunotherapy with Cyclophosphamide and Effector T Cells oleh Koh Nakata, Ichiei Narita, Hiroshi Kagamu, Satoshi Watanabe, Takao Miyabayashi, Junko Baba, Takeshi Ota, Hiroshi Tanaka, Koki Matsuyama, Hirohisa Yoshizawa

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Effect of inhaled corticosteroids on bronchial asthma in Japanese athletes

    Effect of inhaled corticosteroids on bronchial asthma in Japanese athletes oleh Yoshifumi Hoshino, Toshiyuki Koya, Hiroshi Kagamu, Keisuke Tsukioka, Mio Toyama, Takuro Sakagami, Takashi Hasegawa, Ichiei Narita, Masaaki Arakawa, Eiichi Suzuki

    Diterbitkan 2015-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations.

    DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations. oleh Koichiro Nozaki, Hiroshi Kagamu, Satoshi Shoji, Natsue Igarashi, Aya Ohtsubo, Masaaki Okajima, Satoru Miura, Satoshi Watanabe, Hirohisa Yoshizawa, Ichiei Narita

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure

    Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure oleh Kyoichi Kaira, Kunihiko Kobayashi, Ayako Shiono, Ou Yamaguchi, Kosuke Hashimoto, Atsuto Mouri, Shun Shinomiya, Yu Miura, Hisao Imai, Hiroshi Kagamu

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer

    Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer oleh Kyoichi Kaira, Ou Yamaguchi, Tomonori Kawasaki, Kousuke Hashimoto, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Kobayashi, Masanori Yasuda, Hiroshi Kagamu

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Efficacy of Using the Japanese Version of the Asthma Control Test for Determing the Level of Asthma Control in Clinical Settings

    Efficacy of Using the Japanese Version of the Asthma Control Test for Determing the Level of Asthma Control in Clinical Settings oleh Takashi Hasegawa, Toshiyuki Koya, Takuro Sakagami, Hiroshi Kagamu, Hidenori Kawakami, Katsuhito Hara, Fumitoshi Yoshimine, Masaaki Arakawa, Fumitake Gejyo, Ichiei Narita, Eiichi Suzuki

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Influence of Underweight on Asthma Control

    Influence of Underweight on Asthma Control oleh Toshiki Furukawa, Takashi Hasegawa, Kazuo Suzuki, Toshiyuki Koya, Takuro Sakagami, Akira Youkou, Hiroshi Kagamu, Masaaki Arakawa, Fumitake Gejyo, Ichiei Narita, Eiichi Suzuki

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer

    Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies i... oleh Takahiro Uchida, Kyoichi Kaira, Ou Yamaguchi, Atsuto Mouri, Ayako Shiono, Yu Miura, Kosuke Hashimoto, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu

    Diterbitkan 2019-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients

    Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients oleh Ayako Shiono, Kyoichi Kaira, Atsuto Mouri, Ou Yamaguchi, Kosuke Hashimoto, Takahiro Uchida, Yu Miura, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu

    Diterbitkan 2019-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers

    Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers oleh Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Shun Shinomiya, Tomoe Akagami, Hisao Imai, Kunihiko Kobayashi, Hiroshi Kagamu

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab

    Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab oleh Ou Yamaguchi, Kyoichi Kaira, Shun Shinomiya, Atsuto Mouri, Kosuke Hashimoto, Ayako Shiono, Yu Miura, Tomoe Akagami, Hisao Imai, Kunihiko Kobayashi, Hiroshi Kagamu

    Diterbitkan 2021-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer

    Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer oleh Hisao Imai, Erika Naito, Ou Yamaguchi, Kosuke Hashimoto, Hidetoshi Iemura, Yu Miura, Ayako Shiono, Atsuto Mouri, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: